Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOFT-HF: Nocturnal Oxygen Therapy in Heart Failure and Central Sleep Apnea
NCT03745898Phase 3Terminated
- Sponsor
- Brigham and Women's Hospital
- Start
- Apr 2019
- Primary completion
- Jun 2022
- Modality
- Inhalation Devices
- Countries
- 1
01
Overview
A Phase 3 trial of oxygen in heart failure with reduced ejection fraction (HFrEF), central sleep apnea (CSA), sponsored by Brigham and Women's Hospital. Started Apr 2019; status: terminated.
02
Drugs
oxygen
03
Conditions
heart failure with reduced ejection fraction (HFrEF)central sleep apnea (CSA)
Beyond the preview
Go deeper on NCT03745898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03745898.